<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944658</url>
  </required_header>
  <id_info>
    <org_study_id>112008</org_study_id>
    <secondary_id>2008-004229-40</secondary_id>
    <nct_id>NCT00944658</nct_id>
  </id_info>
  <brief_title>Spondylitis Trial of Apremilast for Better Rheumatic Therapy</brief_title>
  <acronym>START</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of apremilast in AS as measured by improvement in
      patients' signs and symptoms of the disease and changes in imaging. Additionally the safety
      and tolerability of apremilast in AS will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presently, there are very few treatments available which affect the progression of the
      disease in the spine. The only proven treatment is the use of drugs inhibiting tumour
      necrosis factor alpha (TNF). However, there are limitations with this treatment in that it
      needs to be administered via an injection and is also very expensive. Therefore it is
      necessary to develop new therapeutic agents for this condition.

      Apremilast (the study drug) is an oral tablet which has been shown to inhibit TNF production
      in a mouse model of inflammation. It has also been used in clinical trials for asthma and
      psoriasis in humans with good affect and tolerability.

      These studies were funded by Celgene Corporation and they will be funding this study.

      The patients will be recruited from hospitals by Consultant referral. The patients will have
      had AS for at least 2 years and their symptoms will have been uncontrolled on conventional
      non−steroidal anti−inflammatory drugs such as ibuprofen. Patients will be randomised to
      either receive apremilast or a placebo and treated over a period of 12 weeks. They will then
      be followed up for 28 days after the treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Apremilast on the Signs and Symptoms of AS, Night Pain From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>This endpoint the night time pain score change was recorded by questionnaire to evaluate the Apremilast effect on symptom, higher reduction better improvement.
scale is 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Apremilast in Patients With AS, Changes in BASFI Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Bath Ankylosing Spondylitis Functional Index (BASFI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Safety and Tolerability of Apremilast in AS, Number of Participants With Adverse Events</measure>
    <time_frame>16 weeks</time_frame>
    <description>To evaluate the safety and tolerability of Apremilast in AS, the investigator recorded the incidence of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo twice a day for 12 weeks, 4 weeks follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg twice a day for 12 weeks, 4 weeks follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
    <arm_group_label>Apremilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (sugar pill)</intervention_name>
    <description>twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent to participate in this trial

          -  Diagnosis of ankylosing spondylitis as defined by the modified New York criteria
             (1984) as follows:

               1. a history of inflammatory back pain;

               2. limitation of motion of the lumbar spine in both the sagittal and frontal planes;

               3. limited chest expansion, relative to standard values for age and sex;

               4. definite radiographic / imaging evidence of sacroiliitis and/or spinal
                  inflammation

          -  Patients must have daily spinal pain and stiffness for at least 2 weeks prior to
             randomization. This is defined by having a score of &gt;1 on questions #2 and #5 of the
             BASDAI score for the 2 weeks prior to randomization.

          -  Patients receiving NSAIDS and/or COX-2 inhibitors must be on stable doses for at least
             2 weeks prior to randomization.

          -  Age &gt;18 years

          -  Male and female patients, who are not surgically sterile or postmenopausal, must use
             reliable methods of birth control for the duration of the study. Males must agree to
             use barrier contraception for 3 months following the end of the trial.

          -  Women of childbearing potential, not surgically sterile or postmenopausal, must have a
             negative serum beta HCG.

        Exclusion Criteria:

          -  Use of DMARDs (methotrexate, d-penicillamine, sulfasalazine, azathioprine,
             hydroxychloroquine, or gold) within 8 weeks of randomization.

          -  Use of systemic corticosteroids within 4 weeks of randomization

          -  Use of intravenous or intra-articular corticosteroids within 4 weeks of randomization

          -  Use of TNF alpha blockers (eg, infliximab, adalimumab) or etanercept as follows:

        Compound PK Exclusion period Etanercept T ½ = 102 hrs = 4.25 days 4 weeks Adalimumab T ½ 2
        wks; 5 half lives 10 weeks 10 weeks Infliximab T ½ 7.7-9.5 d 12 weeks 8 weeks after
        maintenance dose median infx conc 0.5-6 mcg/ml

          -  Therapy with an investigational agent within 30 days of randomization or 5 half-lives
             (pharmacokinetic or pharmacodynamic), which ever is longer

          -  Known HIV or hepatitis B or C infection

          -  Exclusion of tuberculosis (TB)

               -  History of active Mycobacterium tuberculosis infection (any subspecies) within 3
                  years prior to the screening visit. Infections that occurred &gt; 3 years prior to
                  entry must have been effectively treated.

               -  History of incompletely treated latent Mycobacterium tuberculosis infection (as
                  indicated by a positive Purified Protein Derivative [PPD] skin test)

               -  Clinically significant abnormality on chest x-ray (CXR) if mantoux &gt;5mm or
                  ELISPOT positive

          -  History of other rheumatic autoimmune diseases (eg, systemic lupus erythematosus,
             rheumatoid arthritis, etc.)

          -  Pregnant or nursing women

          -  Any condition, in the investigator's opinion, which places the patient at an undue
             risk by participating in the study.

          -  Contraindication to MRI and other MRI exclusions following local centre guidelines
             (Appendix H)

          -  An estimated glomerular filtration rate (eGFR) of &lt; 60 ml/min (because of the small
             risk of nephrogenic sclerosing fibrosis with gadolinium intravenous contrast), if
             patient is to have MRI with gadolinium contrast .

          -  Claustrophobia

          -  Hemoglobin &lt; 9 g/dL

          -  White blood cell (WBC) count &lt; 3000 /μL (≥ 3.0 X 109/L) and ≥ 14,000/μL (≥ 20 X 109/L)

          -  Neutrophils &lt; 1500 /μL (&lt; 1.5 X 109/L)

          -  Platelets &lt; 100,000 /μL (&lt; 100 X 109/L)

          -  Serum creatinine &gt; 1.5 mg/dL (&gt; 132.6 μmol/L)

          -  Total bilirubin &gt; 2.0 mg/dL

          -  Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and
             alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) &gt; 1.5x upper
             limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Taylor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kennedy Institute Clinical Trials Unit, 4 West, Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, Paterson E, Chowdhury M, McClinton C, Taylor PC. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013 Sep 1;72(9):1475-80. doi: 10.1136/annrheumdis-2012-201915. Epub 2012 Sep 14.</citation>
    <PMID>22984171</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <results_first_submitted>August 22, 2019</results_first_submitted>
  <results_first_submitted_qc>November 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2019</results_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
        </group>
        <group group_id="P2">
          <title>Apremilast</title>
          <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
        </group>
        <group group_id="B2">
          <title>Apremilast</title>
          <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.21" spread="13.3"/>
                    <measurement group_id="B2" value="44.88" spread="11.1"/>
                    <measurement group_id="B3" value="42.95" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
          <description>The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue, 0 being no problem and 10 being the worst problem</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.36" spread="1.75"/>
                    <measurement group_id="B2" value="4.79" spread="2.16"/>
                    <measurement group_id="B3" value="4.57" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Functional Index (BASFI)</title>
          <description>A visual analogue scale with 0 being &quot;easy&quot; and 10 &quot;impossible&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.19" spread="2.2"/>
                    <measurement group_id="B2" value="4.55" spread="2.42"/>
                    <measurement group_id="B3" value="3.87" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP C-reactive protein</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.24" spread="2.56"/>
                    <measurement group_id="B2" value="11.37" spread="12.12"/>
                    <measurement group_id="B3" value="8.8" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline</title>
        <description>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline</title>
          <description>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="1.47"/>
                    <measurement group_id="O2" value="-1.59" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes of Apremilast on the Signs and Symptoms of AS, Night Pain From Baseline</title>
        <description>This endpoint the night time pain score change was recorded by questionnaire to evaluate the Apremilast effect on symptom, higher reduction better improvement.
scale is 0-10</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Apremilast on the Signs and Symptoms of AS, Night Pain From Baseline</title>
          <description>This endpoint the night time pain score change was recorded by questionnaire to evaluate the Apremilast effect on symptom, higher reduction better improvement.
scale is 0-10</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="2.75"/>
                    <measurement group_id="O2" value="-0.81" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Apremilast in Patients With AS, Changes in BASFI Score</title>
        <description>Bath Ankylosing Spondylitis Functional Index (BASFI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Apremilast in Patients With AS, Changes in BASFI Score</title>
          <description>Bath Ankylosing Spondylitis Functional Index (BASFI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="1.61"/>
                    <measurement group_id="O2" value="-1.74" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>ANCOVA</method>
            <method_desc>Rank Ancova</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Safety and Tolerability of Apremilast in AS, Number of Participants With Adverse Events</title>
        <description>To evaluate the safety and tolerability of Apremilast in AS, the investigator recorded the incidence of adverse events.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Safety and Tolerability of Apremilast in AS, Number of Participants With Adverse Events</title>
          <description>To evaluate the safety and tolerability of Apremilast in AS, the investigator recorded the incidence of adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo twice a day for 12 weeks, 4 weeks follow up
Placebo (sugar pill): twice a day</description>
        </group>
        <group group_id="E2">
          <title>Apremilast</title>
          <description>30 mg twice a day for 12 weeks, 4 weeks follow up
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>raised serum amylase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoe</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It was most likely underpowered to detect a signiﬁcant beneﬁt of Apremilast in AS patients because no information on an effect size was available to aid in the study design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Taylor</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0) 2075941872</phone>
      <email>jrco@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

